Towards a Self‐Adjuvanting Multivalent B and T cell Epitope Containing Synthetic Glycolipopeptide Cancer Vaccine
Résumé
A new generation of synthetic cancer vaccine: the first self-adjuvanting vaccine prototype combining a cluster of B cell epitope, a CD4+ T helper cell epitope, a CD8+ T cell epitope, and an immunoadjuvant has been synthesized by a chemoselective strategy. Vaccination of mice with this molecularly defined construction induces a strong protection against tumors.